Table 3.
An overview of aspirin trials for the prevention of primary events
| PHS50 | BDT51 | HOT52 | WHS53 | PPP54 | TPT55 | JPAD56 | |
|---|---|---|---|---|---|---|---|
| Main country | US | UK | 26 countries | US | Italy | UK | Japan |
| Aspirin dose | 325 mg qod | 500 mg/day | 75 mg/day | 100 mg qod | 100 mg/day | 75 mg/day | 81–100 mg/day |
| Patients (n) | 22,071 | 5139 | 18,790 | 39,876 | 4495 | 5499 | 2539 |
| Reduction in CV events (%) | 44 (MI) | 10 (mortality) | 15 (major CV events) | 17 (stroke) | 23 (composite CV endpoint) | 20 (IHD) | 20 32 (≥65 years) |
| Conclusions | Aspirin reduces MI | No significant difference between aspirin or placebo | Aspirin reduces major CV events | Aspirin reduces stroke (no effect on MI or CV death) | Terminated early | Aspirin reduces nonfatal IHD | Aspirin beneficial in older patients |
Abbreviations: PHS, Physicians’ Health Study; BDT, British Male Doctors’ Trial; HOT, Hypertension Optimal Trial; WHS, Women’s Health Study; PPP, Primary Prevention Project; TPT, Thrombosis Prevention Trial; JPAD, Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes; CV, cardiovascular; IHD, ischemic heart disease; qod, once daily.